Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 30

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 30
---
 currently approved non-selective
TNF inhibitors that inhibit both sTNF and tmTNF. Protecting the function of tmTNF and TNF receptors while neutralizing the function of
sTNF is a potent anti-inflammatory strategy that does not cause immunosuppression or demyelination which occur in the currently approved
non-selective TNF inhibitors. Currently approved non-selective TNF inhibitors treat autoimmune disease, but are contraindicated in patients
with infection, cancer and neurologic diseases because they increase the risk of infection, cancer and demyelinating neurologic diseases,
respectively; these safety problems are due to off-target effects on inhibiting tmTNF. The NK platform targets the dysfunctional natural
killer cells in patients with cancer. NK cells are part of the normal immunologic response to cancer with important roles in immunosurveillance
to prevent cancer and in preventing relapse by eliminating residual disease. Residual disease is the cancer left behind after therapy
is finished. Residual disease can grow to cause relapse. The mechanism by which INKmune improves the ability of the patient’s NK
cells to kill their cancer is complex. The NK cells of cancer patients lose the ability to bind and kill cancer cells. A measure of NK
cell binding to cancer cells is avidity. The higher the avidity, the greater the bond between the NK cell to cancer cell and thus the
greater NK killing of cancer cells. INKmune increases NK avidity and further improves mitochondrial function and upregulates nutrient
receptors. These metabolic changes may help the INKmune primed NK cell to function in the hostile tumor microenvironment and persist much
longer. These mechanisms improve the ability of INKmune primed NK cells to overcome the immune evasion of the patient’s cancer cells.
We believe INKmune is best used to eliminate residual disease after the patient has completed other cancer therapies. Both the DN-TNF
platform and the INKmune platform can be used to treat multiple diseases. The DN-TNF platform will be used as an immunotherapy for the
treatment of cancer and neurodegenerative disease. INKmune is being developed to treat NK sensitive hematologic malignancies and solid
tumors.

We believe our DN-TNF platform
can be used as a CNS (“central nervous system”) therapy to target glial activation to prevent progression of Alzheimer’s
disease (“AD”); to target neuroinflammation in treatment